Pharma Co. Brass Overhyped ALS Drug Efficacy, Suit Says
By Sydney Price · March 22, 2024, 10:41 PM EDT
Executives and directors of neurodegenerative disease drugmaker Brainstorm Cell Therapeutics have been hit with a proposed class action alleging they damaged the company by overstating the effectiveness of its Lou Gehrig's disease drug even...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login